ArticleJournal of feline medicine and surgery2024
Transmucosal glucagon rapidly increases blood glucose concentration in healthy cats.
Article in Journal of feline medicine and surgery, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- iCatCare 2025 consensus guidelines on the diagnosis and management of diabetes mellitus in cats.Journal of feline medicine and surgery · 2025Guideline
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo evaluate the effect of transmucosal glucagon powder (Baqsimi; Amphastar Pharmaceuticals) on blood glucose (BG) concentrations in healthy cats and describe adverse reactions to its administration.
methodsA randomized, controlled, crossover study was conducted on six healthy cats with a 7-day washout period between treatments. Transmucosal glucagon powder was administered intranasally and rectally and compared with intranasal placebo. Blood was collected at -15 and -1 mins before glucagon administration and 5, 15, 25, 35, 45 and 60 mins after to evaluate BG, plasma glucagon concentrations (pGlucagon) and plasma potassium concentrations (K
resultsMedian pGlucagon in the nasal and rectal groups increased from baseline (nasal: 12.2 pmol/l, range 3.5-44.1; rectal: 6.9 pmol/l, range 2.9-21.1) to 218.5 pmol/l (range 7.9-349.8; CONCLUSIONS AND RELEVANCE: Transmucosal glucagon administration is effective in raising BG with minimal side effects in healthy cats. Future studies are needed to quantify the efficacy and safety of transmucosal glucagon in diabetic cats, especially during hypoglycemic crises.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.